Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors

Hong Bian1, Ji Zhang, Ping Wu

  • 1Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.

Biochemical Pharmacology
|October 23, 2004
PubMed

Insights

Rats exhibit higher susceptibility to phosphodiesterase 4 (PDE4) inhibitor toxicity due to elevated PDE4 expression. This suggests PDE4 inhibitors may be safer for humans compared to rats and monkeys.

Area of Science:

  • Pharmacology
  • Toxicology
  • Biochemistry

Background:

  • Rats show increased susceptibility to phosphodiesterase 4 (PDE4) inhibitor toxicity.
  • The biochemical basis for this higher susceptibility requires elucidation.

Purpose of the Study:

  • To compare PDE4 expression and functional relevance in rats, monkeys, and humans.
  • To investigate the biochemical mechanisms underlying PDE4 inhibitor toxicity.

Main Methods:

  • Quantified mRNA expression levels of PDE4 subtypes (4A, 4B, 4C, 4D) in relevant tissues and leukocytes.
  • Assessed PDE4 enzyme activity in leukocytes.
  • Evaluated the potency of PDE4 inhibitors (rolipram, SB 207499, SCH 351591) in inhibiting TNF production and phenylephrine-induced contraction.

Main Results:

  • Rats displayed significantly higher PDE4 mRNA expression than humans.
  • Higher PDE4 expression correlated with increased enzyme activity in rat leukocytes.
  • PDE4 inhibitor potency followed the order: rat > monkey > human for inhibiting TNF production and vascular contraction.

Conclusions:

  • Elevated PDE4 expression levels in rats likely contribute to their heightened susceptibility to PDE4 inhibitor toxicity.
  • PDE4 inhibitors may pose a lower safety risk in humans compared to monkeys and rats.

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacodynamic Responses: Different Types01:03

Pharmacodynamic Responses: Different Types

Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...